Amgen to buy ChemoCentryx for $3.7B
Amgen was having a relatively quiet year on the mergers and acquisitions front, at least until Aug. 4, when the Thousand Oaks-based biotech firm announced it will purchase ChemoCentryx for nearly $3.7 billion. ChemoCentryx is a Silicon Valley biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has Read More →
Region’s stocks slip amid market-wide slide
After years of charging forward, U.S. stocks have gone into hibernation, at least according to the common definition of a bear market: a market-wide decline of 20% or more from a recent peak. Most major indices are down at least that much from their highs earlier this year, with the biggest losses coming June 13. Read More →
Amgen shares drop after earnings release and disclosure of $5B tax dispute
When Thousand Oaks-based Amgen released its financial results for the first quarter of 2022 on April 27, the biggest surprise didn’t come from its dip in net profits or rise in revenue, but from a tax dispute with the Internal Revenue Service. Amgen said it received a notice of deficiency from the IRS on April Read More →
In Thousand Oaks, biotech execs discuss industry’s ‘rising tide,’ lament area’s lack of housing
In a dark period for the Ventura County economy, immediately before and during the COVID-19 pandemic, the biotechnology sector in the Conejo Valley has been a bright spot. The sector has grown in jobs, economic output and new businesses since 2019, even when the county as a whole has not, according to data presented on Read More →
Amgen shares jump after company announces buyback plan and long-term projections
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen reports revenue spike from COVID treatment collaboration
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen inks drug development deal worth up to $1.9B
Thousand Oaks-based Amgen has reached an agreement with Generate Biomedicines, a Massachusetts-based therapeutics company, to research, discover and create protein therapeutics, the company announced Jan. 6. According to the agreement, Amgen, one of the largest biotech companies in the world, will pay $50 million up front to fund the initial five programs, with a potential Read More →
